DEPLOYDatabase

Incident · Regulatory action

FDA warning letter to Whoop: Blood Pressure Insights marketed beyond clearance

On July 14 2025 the FDA issued Whoop a warning letter (MARCS-CMS 709755) stating that the Blood Pressure Insights (BPI) daily systolic/diastolic estimation feature on the WHOOP MG / Life membership is an unapproved medical device marketed without clearance, since BP estimation is inherently tied to diagnosis of hypo-/hypertension. Whoop publicly disagreed (Jul 15 2025) and BPI remained accessible; as of mid-2026 the dispute is UNRESOLVED with no recall. The load-bearing marketing-beyond-clearance exemplar of the biometric cohort.

Occurred 2025-07-14 · Whoop (5.0 / MG) · Whoop

How to read this record

Incident records on DEPLOY are compiled from public sources (regulatory filings, news reports, and operator disclosures) and reflect what has been reported and tracked to date. They are not legal findings, determinations of fault, or safety ratings, and may be updated as new information is verified. See the sources below for the underlying references.
Track FDA warning letter to Whoop: Blood Pressure Insights marketed beyond clearance

Machine-readable surfaces

Outcomes (1)

  • regulatory actionverified

Revision history (1)

  • 2026-06-05 · outcome_class

Outcome rows carry verification_posture independently. Revision events carry basis (verified_court_filing, verified_insurance, reported_press, estimate, undisclosed). The framework records outcomes only when verifiable; absence is honest absence, not a claim of no-impact.

Sources (2)

  1. FDA · https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/whoop-inc-709755-07142025
  2. MobiHealthNews · https://www.mobihealthnews.com/news/whoop-receives-warning-letter-fda-blood-pressure-insights

Common questions

What happened in FDA warning letter to Whoop: Blood Pressure Insights marketed beyond clearance?
On July 14 2025 the FDA issued Whoop a warning letter (MARCS-CMS 709755) stating that the Blood Pressure Insights (BPI) daily systolic/diastolic estimation feature on the WHOOP MG / Life membership is an unapproved medical device marketed without clearance, since BP estimation is inherently tied to diagnosis of hypo-/hypertension. Whoop publicly disagreed (Jul 15 2025) and BPI remained accessible; as of mid-2026 the dispute is UNRESOLVED with no recall. The load-bearing marketing-beyond-clearance exemplar of the biometric cohort.
When did this incident occur?
The incident is recorded as occurring on July 14, 2025 on the DEPLOY registry. The date reflects the underlying real-world event, not the registry record's creation date.
What robot was involved in FDA warning letter to Whoop: Blood Pressure Insights marketed beyond clearance?
Whoop (5.0 / MG) by Whoop is the recorded robot involved in this incident.
Has anyone responded to FDA warning letter to Whoop: Blood Pressure Insights marketed beyond clearance?
No responses to this incident are recorded on the DEPLOY registry. Operators, manufacturers, or affected parties can submit responses to the editorial team; absence is not a guarantee no response was issued.
What is the current status of FDA warning letter to Whoop: Blood Pressure Insights marketed beyond clearance?
This incident is an active record on the DEPLOY registry; no retraction or correction has been issued.
Methodology: Verified · 2 sources (1 primary) · last reviewed 2026-06-24

Verification posture

Verified

High confidence

Review state

Stable

Last reviewed 2026-06-24

Sources by quality tier

1
primary-fda-database
FDA database
1
unclassified
Unclassified source

The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.

Methodology surface for FDA warning letter to Whoop: Blood Pressure Insights marketed beyond clearance.

Deploy Watch

Track this incident.

We notify you when the regulator updates the record, the remedy status changes, or a related incident surfaces.

Canonical ID 2551f142-584e-48a5-978d-ff8c82023c01